It’s finally here: 3D-printed pills and technology in pharma
September 29, 2015Manufacturing and Production 3-D printing, 3d printing, Aprecia, Spritam, manufacturing, production
The notion of tailor-made drugs, which are customised to an individual patient’s needs, has seen remarkable progress of late. This …
Georges Gemayel appointed non-executive chairman of Enterome
September 29, 2015Manufacturing and Production
Drug and diagnostics development firm Enterome Bioscience SA has appointed Dr Georges Gemayel to the Enterome board as a non-executive …
UN calls on pharma industry to make medicines more affordable
September 29, 2015Manufacturing and Production AIDS, HIV, Michel Sidibe, UNAIDS, United Nations, antiretroviral treatments
The United Nations AIDS agency, UNAIDS, has called on governments and the pharmaceutical industry to ensure that medicines remain accessible …
FDA withdraws approval for Sun Pharma’s epilepsy drug
September 29, 2015Manufacturing and Production Elepsia, FDA, Sun Pharma, epilepsy, levetiracetam, manufacturing, productions, seizures
Manufacturing problems at Sun Pharma’s production site has led the FDA to revoke the company’s approval for Elepsia XR for …
Bristol-Myers Squibb notches kidney cancer first with Opdivo
September 28, 2015Research and Development Afinitor, Bristol-Myers Squibb, Kidney cancer, advanced kidney cancer, everolimus, nivolumab, opdivo, renal cell carcinoma
Bristol-Myers Squibb has announced positive results from a Phase III study comparing Opdivo to Afinitor, the Novartis treatment that is …
Alexion to challenge Canadian price of Soliris in court
September 28, 2015Sales and Marketing Alexion, Canada, Drug pricing, Patented Medicine Prices Review Board, eculizumab, soliris
Alexion Pharmaceuticals is taking the Canadian government to court for its attempt to lower the price of the rare disease …
Sanofi and Regeneron given European nod for Praluent
September 28, 2015Sales and Marketing European Commission, Regeneron, Sanofi, alirocumab, high cholesterol, marketing authorisation, praluent
The European Commission (EC) has approved the marketing authorisation of Sanofi and Regeneron’s cholesterol drug Praluent. The heart drug is …
FDA approves Novo Nordisk’s diabetes drugs
September 28, 2015Sales and Marketing FDA, Novo Nordisk, Ryzodeg, Tresiba, diabetes, insulin
The FDA has approved two Novo Nordisk drugs, Tresiba and Ryzodeg, for the treatment of type 2 diabetes in adults.The …
Brandicourt set to continue Sanofi restructure
September 28, 2015Sales and Marketing Merial, Sanofi, olivier brandicourt, restructuring, sales, spin-off
Sanofi chief executive Olivier Brandicourt is considering sales or spin-offs of a number of the company’s divisions, as part of …
Legal analysis: compliance top of the agenda for big pharma
September 25, 2015Medical Communications, Sales and Marketing lawyers, legal, pharma industry, reputation
Do you think big pharma suffers from a negative image, and if so, to what extent do you think this …
Synergy Vision shortlisted for Women of the Future awards
September 25, 2015Medical Communications Synergy Vision, medical communications, medical communications agency, women, women of the future awards
Synergy Vision has been shortlisted for the Women of the Future (“WOF”) Awards, the movement recognising and nurturing young female …
ImmunoCellular awarded $19.9 million grant for ICT-107 phase 3 trial for glioblastoma
September 25, 2015Research and Development California Institute for Regenerative Medicine, Cancer, ICT-107, brain cancer, glioblastoma
ImmunoCellular Therapeutics has been awarded a $19.9 million grant by California Institute for Regenerative Medicine (CIRM), California’s stem cell agency, …
Novartis’ new heart failure medicine recommended for EU approval
September 25, 2015Medical Communications, Research and Development Entresto, Novartis, eams, heart failure
The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Novartis’s heart failure medication Entresto …
Merck and Wayra to tackle NHS funding gap with startup rewards programme
September 25, 2015Research and Development MSD, Merck
Merck Sharpe and Dohme (MSD) and Wayra Open Future, Telefonica’s digital start up accelerator, are investing in digital innovation in …
ABPI responds to UK medicines cost controversy
September 25, 2015Medical Communications, Sales and Marketing ABPI, Cancer Drugs Fund, NHS
Alison Clough, acting CEO of the Association of the British Pharmaceutical Industry (ABPI), has responded to recent reports in the …
Genetic study reveals new associations with lung disease and smoking behaviour
September 25, 2015Medical Communications, Research and Development COPD, lung cancer, smkoing
New research published in The Lancet Respiratory Medicine and presented at this year’s European Respiratory Society (ERS) Congress in Amsterdam …
Novartis launches affordable medicines portfolio for lower-income countries
September 24, 2015Manufacturing and Production, Sales and Marketing Novartis
Novartis has announced the launch of ‘Novartis Access’, a portfolio of 15 medicines to treat chronic diseases in low and …
NICE approves first in new class of leukaemia drugs
September 24, 2015Cancer Drugs Fund, Gilead Sciences, NHS, NICE, idelalisib, leukaemia, zydelig
NICE has issued final draft guidance which recommends that Gilead’s Zydelig should be made available on the NHS for some …
Turing will drop price of Daraprim following outrage
September 24, 2015Sales and Marketing Daraprim, Impax Laboratories, Martin Shkreli, Turing Pharmaceuticals, toxoplasmosis
Martin Shkreli, whose company Turing Pharmaceuticals increased the price of Daraprim more than fifty-fold overnight, has been forced to backpedal …
Boehringer and BioMed X crowdsource top scientists to fight COPD
September 23, 2015Research and Development Boehringer Ingelheim, COPD
Boehringer Ingelheim and BioMed X have used a crowdsourcing strategy to establish a global research team to collaborate on the …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
